Tumor Specific Conversion of a Pyrimidine Antimetabolite
5-Fluorouracil (5-FU) was the first of a series of pyrimidine antimetabolites possessing a growth inhibitory effect on transplantable tumors. Its usefulness in clinical cancer chemotherapy is established. Considerable efforts have been made towards finding 5-FU derivatives with better antitumor activity and less toxicity. 5′-dFUR, a novel pyrimidine analog, has been shown to possess both a high cytostatic activity against a broad spectrum of experimental tumors and a low toxicity. In vitro, however, medium concentrations needed for 50% growth inhibition are much higher for 5′-dFUR than for 5-FU or 2′-deoxy-5-fluorouridine (FUdR) and vary markedly from cell line to cell line.
KeywordsLewis Lung Carcinoma Transplantable Tumor Pyrimidine Nucleoside Pyrimidine Analog Average Tumor Weight
Unable to display preview. Download preview PDF.